Related Experiment Video
Updated: Jun 5, 2025
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Limosilactobacillus Fermentun ZS09 Can Improve Antibiotic-Induced Motor Dysfunction in Mice by Regulating the
Yang Yang1, Yuanji Zhao2, Huan Lei1
1College of Physical Education, Chengdu Sport University, Chengdu, Sichuan, 610041, People's Republic of China.
Purpose:
When consumed in appropriate quantities, probiotics, which are live microorganisms, are good for health. In this study, a mouse model of antibiotic-induced dyskinesia was established using a sterile mixed antibiotic solution to investigate the preventive impact of Limosilactobacillus fermentum ZS09 (LFZS09) on this condition in mice.
Methods:
Following modeling, alterations in the serum and brain tissue of mice were assessed for motor measures such as running and swimming, malondialdehyde (MDA), superoxide dismutase, reduced glutathione, interleukin (IL-6, IL-10), and tumor necrosis factor (TNF)-α. The mouse cecum was used to evaluate the relative mRNA expression levels of the intestinal barrier genes, namely occludin-1, zona occludens-1 (ZO-1), and claudin-1. The relative mRNA expression levels of cAMP-response element binding protein (CREB), extracellular signal-regulated kinase (ERK), and brain-derived neurotrophic factor (BDNF) genes in the mouse brain tissue were also evaluated.
Results:
Compared with the model group, LFZS09 considerably increased the swimming and running duration of mice, significantly decreased the levels of the inflammatory factors TNF-α and IL-6 and increased SOD expression in the mouse brain, and decreased MDA accumulation in the mouse brain and serum. Furthermore, LFZS09 upregulated occludin-1 gene expression in the cecal tissue to maintain the intestinal barrier, which in turn maintained the normal physiological function of the body. LFZS09 also enhanced the effect of BDNF and increased the expression of BDNF metabolic pathway-related genes, namely CREB, ERK1/2, and BDNF, in the mouse brain tissue. LFZS09 increased the number of Lactobacillus and Bifidobacterium in the gut of mice with motor dysregulation, and decreased the number of Enterococcus and Clostridium perfringens.
Conclusion:
The findings indicate that LFZS09 regulates antibiotic-induced motor impairment in mice, thereby offering a theoretical foundation for future studies and probiotic or parabiotics production aimed at augmenting motor function.
Insights
Limosilactobacillus fermentum ZS09 (LFZS09) probiotic treatment improved motor function in mice with antibiotic-induced dyskinesia. LFZS09 restored gut microbiota balance and enhanced neurotrophic factors, offering potential for motor function augmentation.
Area of Science:
- Microbiology and Neuroscience
- Gut Microbiome Research
- Probiotic Therapeutics
Background:
- Probiotics, live microorganisms, offer health benefits when consumed appropriately.
- Antibiotic use can disrupt gut microbiota, potentially leading to motor impairments.
- Limosilactobacillus fermentum ZS09 (LFZS09) is a probiotic strain with potential therapeutic applications.
Purpose of the Study:
- To investigate the preventive effects of Limosilactobacillus fermentum ZS09 (LFZS09) on antibiotic-induced dyskinesia in a mouse model.
- To assess the impact of LFZS09 on motor function, gut microbiota, and neuroinflammation in mice.
Main Methods:
- Establishment of a mouse model of antibiotic-induced dyskinesia.
- Assessment of motor function (running, swimming), oxidative stress markers (MDA, SOD), and inflammatory cytokines (IL-6, TNF-α) in serum and brain tissue.
- Evaluation of intestinal barrier gene expression (occludin-1, ZO-1, claudin-1) in cecal tissue and neurotrophic factor pathway gene expression (CREB, ERK, BDNF) in brain tissue.
- Analysis of gut microbiota composition (Lactobacillus, Bifidobacterium, Enterococcus, Clostridium perfringens).
Main Results:
- LFZS09 significantly improved motor function, increasing running and swimming duration in mice.
- LFZS09 reduced levels of inflammatory factors (TNF-α, IL-6) and oxidative stress markers (MDA) while increasing SOD expression.
- LFZS09 upregulated intestinal barrier genes, enhanced BDNF pathway gene expression, and modulated gut microbiota composition, increasing beneficial bacteria and decreasing harmful ones.
Conclusions:
- LFZS09 demonstrates a significant preventive effect against antibiotic-induced motor impairment in mice.
- LFZS09 acts by maintaining intestinal barrier integrity, enhancing neurotrophic support, and rebalancing gut microbiota.
- These findings provide a theoretical basis for developing LFZS09-based probiotics for augmenting motor function.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...